Skip to main content
Top

04-08-2015 | Non-melanoma skin cancer | Article

Staging and Management of High-Risk Cutaneous Squamous Cell Carcinoma

Journal: Current Dermatology Reports

Authors: Pritesh S. Karia, Emily Stamell Ruiz, Chrysalyne D. Schmults

Publisher: Springer US

Abstract

Cutaneous squamous cell carcinoma (CSCC) is among the most common malignancies in the USA and among Caucasians. Most patients with CSCC have an excellent prognosis. However, there is a high-risk subset that carries an elevated risk of local recurrence, nodal metastasis, and death. Treatment modalities for local disease are highly effective and even early nodal disease is highly curable; however, once uncontrollable loco-regional disease or distant metastasis develops, survival is significantly diminished. Current tumor staging systems for CSCC have limitations and clinicians have little evidence to guide decisions regarding nodal staging and adjuvant therapy. The aim of this review is to highlight the identification and management of high-risk CSCCs, discuss the pitfalls of current staging systems, and introduce novel alternative staging systems for CSCC that have been proposed in recent years.
Literature
1.
Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.CrossRefPubMed
2.
Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer. 1999;81(4):555–9.CrossRefPubMed
3.
Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.CrossRefPubMed
4.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541–7.CrossRefPubMed
5.
Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20.CrossRefPubMed
6.
Roozeboom MH, Lohman BG, Westers-Attema A, Nelemans PJ, Botterweck AA, van Marion AM, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venereol. 2013;93(4):417–21.CrossRefPubMed
7.••
Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327–34. Study comparing the 2010 American Joint Committee on Cancer, 2010 International Union Against Cancer, and Brigham and Women’s Hospital tumor staging systems for cutaneous squamous cell carcinoma.PubMedCentralCrossRefPubMed
8.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: squamous cell skin cancer 2015 [04/08/2015]. Available from: http://​www.​nccn.​org/​professionals/​physician_​gls/​f_​guidelines.​asp.
9.
Edge SB, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer staging manual. 7th ed. New York: Springer; 2010.
10.
Chu MB, Slutsky JB, Dhandha MM, Beal BT, Armbrecht ES, Walker RJ, et al. Evaluation of the definitions of “high-risk” cutaneous squamous cell carcinoma using the American Joint Committee on Cancer staging criteria and National Comprehensive Cancer Network guidelines. J Skin Cancer. 2014;2014:154340.PubMedCentralCrossRefPubMed
11.
Jambusaria-Pahlajani A, Hess SD, Katz KA, Berg D, Schmults CD. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol. 2010;146(11):1225–31.CrossRefPubMed
12.•
Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811–5. Study identifying independent risk factors for nodal metastasis from cutaneous squamous cell carcinoma.CrossRefPubMed
13.
Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.CrossRefPubMed
14.
Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002;28(3):268–73.PubMed
15.
Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4):759–65.CrossRefPubMed
16.
Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115(9):1561–7.CrossRefPubMed
17.
Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer. 2006;106(11):2389–96.CrossRefPubMed
18.
Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer. 1997;79(5):915–9.CrossRefPubMed
19.
Ko CJ, McNiff JM, Glusac EJ. Squamous cell carcinomas with single cell infiltration: a potential diagnostic pitfall and the utility of MNF116 and p63. J Cutan Pathol. 2008;35(4):353–7.CrossRefPubMed
20.
Frierson Jr HF, Cooper PH. Prognostic factors in squamous cell carcinoma of the lower lip. Hum Pathol. 1986;17(4):346–54.CrossRefPubMed
21.
Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149(1):35–41.CrossRefPubMed
22.
Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984;148(4):542–7.CrossRefPubMed
23.
Ross AS, Whalen FM, Elenitsas R, Xu X, Troxel AB, Schmults CD. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35(12):1859–66.CrossRefPubMed
24.
Tavin E, Persky M. Metastatic cutaneous squamous cell carcinoma of the head and neck region. Laryngoscope. 1996;106(2 Pt 1):156–8.CrossRefPubMed
25.
Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Asschenfeldt B, Stockfleth E, et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(4):1029–36.CrossRefPubMed
26.
Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506–9.CrossRefPubMed
27.
Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2 Pt 1):177–86.CrossRefPubMed
28.
Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999;85(8):1758–64.CrossRefPubMed
29.
Euvrard S, Kanitakis J, Pouteil-Noble C, Disant F, Dureau G, Finaz de Villaine J, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Trasnplant Proc. 1995;27(2):1767–8.
30.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.CrossRefPubMed
31.
Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 2005;53(6):1067–71.CrossRefPubMed
32.
Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs’ surgery in patients with chronic lymphocytic leukemia. Dermatol Surg. 2005;31(1):38–42. discussion.CrossRefPubMed
33.
Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150(3):280–7.CrossRefPubMed
34.
Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol. 2015. doi:10.​1001/​jamadermatol.​2015.​1702.PubMed
35.
Wermker K, Kluwig J, Schipmann S, Klein M, Schulze HJ, Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. Eur J Surg Oncol. 2015;41(1):128–35.CrossRefPubMed
36.
Greene FL, Page DL, Fleming ID, et al., editors. American Joint Committee on Cancer staging manual. 6th ed. New York: Springer; 2002.
37.
Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64(6):1051–9.CrossRefPubMed
38.
Breuninger H, Brantsch K, Eigentler T, Hafner HM. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges. 2012;10(8):579–86.PubMed
39.
Buethe D, Warner C, Miedler J, Cockerell CJ. Focus issue on squamous cell carcinoma: practical concerns regarding the 7th edition AJCC Staging Guidelines. J Skin Cancer. 2011;2011:156391.PubMedCentralCrossRefPubMed
40.•
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, Gelfand JM, Whalen FM, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402–10. Study evaluating the 2010 American Joint Committee on Cancer tumor staging system for cutaneous squamous cell carcinoma and proposing an alternative tumor staging system.CrossRefPubMed
41.
Dinehart SM, Peterson S. Evaluation of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma and proposal of a new staging system. Dermatol Surg. 2005;31(11 Pt 1):1379–84.PubMed
42.
Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012;82(4):230–3.CrossRefPubMed
43.
Brougham ND, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma—implications on the T-classification system. J Surg Oncol. 2014;110(7):876–82.CrossRefPubMed
44.
Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. 2010;116(5):1298–304.CrossRefPubMed
45.•
Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. Ann Surg Oncol. 2012;19(13):4252–8. Study evaluating the 2010 American Joint Committee on Cancer nodal staging system for cutaneous squamous cell carcinoma and proposing an alternative nodal staging system.CrossRefPubMed
46.
Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17(8):2006–14.CrossRefPubMed
47.
Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.CrossRefPubMed
48.
Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin 2nd RC, Schacherer CW, et al. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012;214(4):608–17. discussion 17–9.CrossRefPubMed
49.•
Brunner M, Ng BC, Veness MJ, Clark JR. Comparison of the AJCC N staging system in mucosal and cutaneous squamous head and neck cancer. Laryngoscope. 2014;124(7):1598–602. Study evaluating and comparing the unified nodal staging system for mucosal and cutaneous squamous cell carcinoma.CrossRefPubMed
50.
De Zinis LO, Bolzoni A, Piazza C, Nicolai P. Prevalence and localization of nodal metastases in squamous cell carcinoma of the oral cavity: role and extension of neck dissection. Eur Arch Otorhinolaryngol. 2006;263(12):1131–5.CrossRefPubMed
51.
Yousem DM, Som PM, Hackney DB, Schwaibold F, Hendrix RA. Central nodal necrosis and extracapsular neoplastic spread in cervical lymph nodes: MR imaging versus CT. Radiology. 1992;182(3):753–9.CrossRefPubMed
52.
Ginsberg LE. MR imaging of perineural tumor spread. Neuroimaging Clin N Am. 2004;14(4):663–77.CrossRefPubMed
53.
Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope. 1992;102(3):281–8.CrossRefPubMed
54.
Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope. 1995;105(2):135–9.CrossRefPubMed
55.
Klode J, Poeppel T, Boy C, Mueller S, Schadendorf D, Korber A, et al. Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol. 2011;25(10):1213–21.CrossRefPubMed
56.
Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiology. 2009;19(3):634–42.CrossRef
57.
Knappe M, Louw M, Gregor RT. Ultrasonography-guided fine-needle aspiration for the assessment of cervical metastases. Arch Otolaryngol. 2000;126(9):1091–6.CrossRef
58.
Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006;32(11):1309–21.PubMed
59.•
Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol. 2015;41(2):197–200. Systematic review of the utility of sentinel lymph node biopsy in high-risk cutaneous squamous cell carcinoma.CrossRefPubMed
60.•
Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150(1):19–24. Study evaluating cutaneous squamous cell carcinoma tumors that may be appropriate for sentinel lymph node biopsy.CrossRefPubMed
61.
Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol. 2005;53(2):261–6.CrossRefPubMed
62.
Lawrence N, Cottel WI. Squamous cell carcinoma of skin with perineural invasion. J Am Acad Dermatol. 1994;31(1):30–3.CrossRefPubMed
63.
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153.PubMedCentralCrossRefPubMed
64.
Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg. 2010;36(10):1544–53.CrossRefPubMed
65.
Ad Hoc Task F, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50.CrossRef
66.
Garcia-Zuazaga J, Olbricht SM. Cutaneous squamous cell carcinoma. Adv Dermatol. 2008;24:33–57.CrossRefPubMed
67.
Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthetic Dermatol. 2010;3(6):20–34.
68.
Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60(2):406–11.CrossRefPubMed
69.
Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35(4):574–85.CrossRefPubMed
70.
Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119(10):1994–9.CrossRefPubMed
71.
Al-Othman MO, Mendenhall WM, Amdur RJ. Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol. 2001;22(6):387–90.CrossRefPubMed
72.
Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010;46(9):1563–72.CrossRefPubMed
73.
O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck. 2002;24(5):417–22.CrossRefPubMed
74.
Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I. Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope. 2003;113(10):1827–33.CrossRefPubMed
75.
Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115(5):870–5.CrossRefPubMed
76.
Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692–6.CrossRefPubMed
77.
Guthrie Jr TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–6.PubMed
78.
Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol. 2000;23(2):181–4.CrossRefPubMed
79.
Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2.CrossRefPubMed
80.
Behshad R, Garcia-Zuazaga J, Bordeaux JS. Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature. Br J Dermatol. 2011;165(6):1169–77.CrossRefPubMed
81.
Watt SA, Pourreyron C, Purdie K, Hogan C, Cole CL, Foster N, et al. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene. 2011;30(46):4666–77.PubMedCentralCrossRefPubMed
82.
Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(17):2659–65.CrossRefPubMed
83.
Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26.CrossRefPubMed
84.
Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047–52.CrossRefPubMed
85.
Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435–46.CrossRefPubMed
86.
Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;85(5):1275–81.PubMedCentralCrossRefPubMed
87.
Veness MJ. Defining patients with high-risk cutaneous squamous cell carcinoma. Australas J Dermatol. 2006;47(1):28–33.CrossRefPubMed
88.•
Tanvetyanon T, Padhya T, McCaffrey J, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015;37(6):840–5. Study evaluating recurrence-free survival in patients receiving adjuvant radiation versus adjuvant chemoradiation for high-risk cutaneous squamous cell carcinoma.CrossRefPubMed